Spotify heads into its May 21 earnings call with options traders meaningfully more defensive than they have been all year — and that shift stands out against a week when the stock itself quietly recovered.
The sharpest signal this week is in options. The put/call ratio jumped to 0.94 on Tuesday — more than three standard deviations above its 20-day mean of 0.83. That's close to the 52-week high of 1.10, and the move happened in a single session while the stock was rebounding 3.2% to $432.75. Investors were buying downside protection into a bounce, not into a sell-off. That asymmetry — calls for the bulls, puts piling in regardless — points to genuine unease ahead of the Q1 print.
The context for that caution is the last earnings reaction. Spotify fell 10.5% the day after its most recent report in late April and extended the move to -15.4% over the following week. The stock is now 9% lower over the past month and down 28% year-to-date, meaning the market came in with relatively muted expectations — yet the options market is clearly not relaxed going into the next one.
Short interest adds a secondary layer of pressure. At 3.4% of the free float, the position is modest rather than extreme. But it has grown 5.1% over the past week and 10.3% over the past month — a steady, deliberate rebuild. Borrowing remains cheap at 0.44% annually, and availability in the lending market is ample, so there is no mechanical squeeze setup here. The borrow market is loose; the shorts are building because they have a view, not because they're trapped. The ORTEX short score has ticked up to 38.1 from 36.3 a week ago — not alarming in isolation, but directionally consistent with the options read.
The Street remains firmly constructive in rating but has been walking down its numbers. After the April earnings miss, virtually every covering firm maintained its positive rating while cutting targets — Goldman Sachs trimmed to $600 from $670, JP Morgan to $600 from $700, and Barclays to $500 from $600, all within the past two weeks. The consensus mean price target is around $509, implying roughly 18% upside from current levels — meaningful, but the gap between the most cautious targets (Cantor Fitzgerald at $430, close to where the stock trades now) and the most bullish ($735 from UBS) tells you the range of outcomes the Street is pricing. The bull case rests on 751 million MAUs, expanding premium gross margins, and the long runway on operating leverage. The bear case is rising content costs, slowing ARPU growth without further price increases, and a valuation — PE near 26x on trailing earnings but EV/EBITDA at 21x — that leaves little room for a revenue miss.
Institutionally, the register is stable. Co-founder Sven Lorentzon holds 9.2% and CEO Daniel Ek 5.8%, with neither having changed their positions recently. BlackRock added a modest 82,000 shares through April, and Capital Research lifted by 551,000 shares in Q1. The more notable item is on the insider sell side: both Co-CEOs — Alex Norstrom and Victor Soderstrom — sold shares on May 5, in transactions totalling roughly $11 million between them. These look like programmatic sales rather than conviction moves given their regularity, but the timing, days before the next earnings release, is worth noting.
With the May 21 call now a week away, the setup to watch is whether the PCR reversion is a single-day spike or the start of sustained defensive positioning — and whether the steady short rebuild accelerates after last quarter's post-earnings drop sets a fresh reference point for bears.
See the live data behind this article on ORTEX.
Open SPOT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
